Lurbinectedin

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C41H44N4O10S
Molecular Weight	784.874
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC6=C5C=C(OC)C=C6)C(=O)OC[C@H](N1[C@@H](O)[C@@H]7CC8=CC(C)=C(OC)C(O)=C8[C@H]2N7C)C9=C%10OCOC%10=C(C)C(OC(C)=O)=C39

InChI

InChIKey=YDDMIZRDDREKEP-HWTBNCOESA-N

InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C41H44N4O10S
Molecular Weight	784.874
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28683469 | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=641468 | https://www.ncbi.nlm.nih.gov/pubmed/28368437 | https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM563557.pdf

Lurbinectedin (PM-01183) - is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death. Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and the DNA repair machinery in tumour cells.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
RNA Polymerase II Transcription 1 Target ID: WP1906 Sources: https://ovariancancernewstoday.com/2017/06/23/ovarian-cancer-therapy-lurbinectedin-by-pharmamar-to-be-marketed-as-zepsyre-once-approved/ \| https://www.pharmamar.com/science-and-innovation/action-mechanisms/ \| https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM563557.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ovarian cancer 160 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28368437 https://clinicaltrials.gov/ct2/show/NCT02421588	Primary		Phase III 665	Unknown Approved Use Unknown
Non-small cell lung cancer 211 Sources: https://clinicaltrials.gov/ct2/show/NCT01951157 http://adisinsight.springer.com/drugs/800030007	Primary		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
153.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24563480	7 mg 1 times / 3 weeks multiple, intravenous dose: 7 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:		LURBINECTEDIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
532.6 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24563480	7 mg 1 times / 3 weeks multiple, intravenous dose: 7 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:		LURBINECTEDIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
51.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24563480	7 mg 1 times / 3 weeks multiple, intravenous dose: 7 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:		LURBINECTEDIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	Disc. AE: Peripheral neuropathy, Myelosuppression... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (>1) Myelosuppression (>1) Neutropenia (>3) Hypoalbuminemia (>3) Febrile neutropenia (>3) Fatigue (>3) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
6.9 mg/m2 1 times / 3 weeks steady, intravenous Highest studied dose Dose: 6.9 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 6.9 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
4 mg/m2 1 times / 3 weeks steady, intravenous MTD Dose: 4 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 4 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	DLT: Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (grade 4, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	DLT: AST increased, Neutropenia... Dose limiting toxicities: AST increased (grade 4, 2 patients) Neutropenia (grade 4, 2 patients) Fatigue (grade 3, 2 patients) Nausea (grade 2, 2 patients) Vomiting (grade 2, 2 patients) Diarrhea (grade 2, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf

AEs

AE	Significance	Dose	Population
Myelosuppression	>1 Disc. AE	3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
Peripheral neuropathy	>1 Disc. AE	3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
Fatigue	>3 Disc. AE	3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
Febrile neutropenia	>3 Disc. AE	3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
Hypoalbuminemia	>3 Disc. AE	3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
Neutropenia	>3 Disc. AE	3.2 mg/m2 1 times / 3 weeks steady, intravenous Recommended Dose: 3.2 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 3.2 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	unhealthy, 60 years (range: 40 - 83 years) Health Status: unhealthy Age Group: 60 years (range: 40 - 83 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
Thrombocytopenia	grade 4, 1 patient DLT	4 mg/m2 1 times / 3 weeks steady, intravenous MTD Dose: 4 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 4 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
Diarrhea	grade 2, 2 patients DLT	5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
Nausea	grade 2, 2 patients DLT	5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
Vomiting	grade 2, 2 patients DLT	5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
Fatigue	grade 3, 2 patients DLT	5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
AST increased	grade 4, 2 patients DLT	5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
Neutropenia	grade 4, 2 patients DLT	5 mg/m2 1 times / 3 weeks steady, intravenous Studied dose Dose: 5 mg/m2, 1 times / 3 weeks Route: intravenous Route: steady Dose: 5 mg/m2, 1 times / 3 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 OATP1B1 1079 OATP1B3 961 OCT1 620 CYP1A2 2153 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060	P-gp 2052 OATP1B3 435 OCT1 393 MATE1 182 BCRP 697 BSEP 63 OAT1 395 OAT3 391 OCT2 434	CYP1A2 832

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0	yes
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0	yes
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0	yes
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0	yes

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=52 Page: 52.0	major
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
BSEP 63	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
MATE1 182	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf#page=11 Page: 11.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf#page=34 Page: 34.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00DJWD	https://www.aablocks.com/goods/Goods/detail?id=AA00DJWD
AbMole Bioscience	M10037	http://www.abmole.com/products/lurbinectedin.html
BLD Pharm	BD00825727	http://www.bldpharm.com/products/497871-47-3.html
Chem Scene	CS-6323	http://www.chemscene.com/497871-47-3.html
Chemspace	CSSS00161189527	https://chem-space.com/CSSS00161189527
DC Chemicals	DC12502	http://www.dcchemicals.com/product_show-Lurbinectedin.html
DC Chemicals	Lurbinectedin	http://www.dcchemicals.com/product_show-Lurbinectedin.html
eNovation Chemicals	D671373	https://www.enovationchem.com/ProductDetails.asp?ProductID=D671373
Excenen	EX-A4316	https://www.excenen.com/searchresultlist.php?id=EX-A4316
Hairui	LUJL028	http://www.hairuichem.com/en/product/497871-47-3.html
MedChem Express	HY-16293	https://www.medchemexpress.com/Lurbinectedin.html
MolPort	MolPort-046-702-163	https://www.molport.com/shop/molecule-link/MolPort-046-702-163
MuseChem	I013699	https://www.musechem.com/product/I013699.html
Selleck Chemicals	S9603	http://www.selleckchem.com/products/lurbinectedin.html
Smolecule	S533851	http://www.smolecule.com/products/s533851
THE BioTek	bt-274785	https://www.thebiotek.com/product/inhibitors/bt-274785

PubMed

Title	Date	PubMed
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.	2017-08-22	28683469
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.	2017-06-01	28368437

Patents

Sample Use Guides

In Vivo Use Guide

Non-Small Cell Lung Cancer: 3.2 mg/m2 Lurbinectedin (PM01183), day 1, 1-hour intravenous, every three weeks

Route of Administration: Intravenous

In Vitro Use Guide

48 hours’ treatment with lurbinectedin (0.3–10 nmol/L) inhibited the proliferation of the ovarian cancer cells of CCC origin in a dose-dependent manner.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:57:20 GMT 2025` Edited by `admin` on `Mon Mar 31 20:57:20 GMT 2025`
Record UNII	2CN60TN6ZS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PM-01183

Preferred Name

English

Lurbinectedin

Official Name

English

LURBINECTEDIN [MI]

Common Name

English

PM1183

Code

English

LURBINECTEDIN [USAN]

Common Name

English

PM-1183

Code

English

TRYPTAMICIDIN

Common Name

English

Lurbinectedin [WHO-DD]

Common Name

English

lurbinectedin [INN]

Common Name

English

(1'R,6R,6AR,7R,13S,14S,16R)-8,14-DIHYDROXY-6',9-DIMETHOXY-4,10,23-TRIMETHYL-19-OXO-2',3',4',6,7,9',12,13,14,16-DECAHYDRO-6AHSPIRO(7,13-AZANO-6,16-(EPITHIOPROPANOOXYMETHANO)(1,3)DIOXOLO(7,8)ISOQUINOLINO(3,2-B)(3)BENZAZOCINE-20,1'-PYRIDO(3,4-B)INDOL)-5-YL

Systematic Name

English

SPIRO(6,16-(EPITHIOPROPANOXYMETHANO)-7,13-IMINO-12H-1,3-DIOXOLO(7,8)ISOQUINO(3,2-B)(3)BENZAZOCINE-20,1'-(1H)PYRIDO(3,4-B)INDOL)-19-ONE, 5-(ACETYLOXY)-2',3',4',6,6A,7,9',13,14,16-DECAHYDRO-8,14-DIHYDROXY-6',9-DIMETHOXY-4,10,23-TRIMETHYL-, (1'R,6R,6AR,7R,1

Systematic Name

English

ZEPSYRE

Brand Name

English

PM01183

Code

English

ZEPZELCA

Brand Name

English

LURBINECTEDIN [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C25760